As a recognized weight loss clinic in Carlsbad that accepts insurance, we aim to make treatment convenient and accessible for everyone
In the presence of GI AEs, one of the first precautions recommended is to extend the titration period or delay dose escalation until symptoms subside
Oral Wegovy (Semaglutide Pill) Approved in December 2025, Oral Wegovy offers a unique option for those who prefer a daily pill over an injection
Currently available treatment with proven outcomes Semaglutide FDA-approved for diabetes (Ozempic), obesity (Wegovy), and CV risk reduction with 7+ years of clinical and post-marketing data Cardiovascular risk reduction Semaglutide SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit Maximum weight loss potential Retatrutide Phase 2 data showed 24.2% weight loss at 48 weeks with weight curves still declining, though Phase 3 confirmation is required Metabolic liver disease (MASLD/MASH) Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, a mechanistic advantage for liver-specific outcomes Oral administration preference Semaglutide Only incretin-class drug available as an oral tablet (Rybelsus), with higher-dose oral formulations under development Type 2 diabetes with established treatment guidelines Semaglutide Integrated into clinical guidelines with multiple approved doses and formulations, extensive comparative data, and guideline positioning Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
2021 Aug 5;385(6):503-515
